Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

NCT05389514 · clinicaltrials.gov ↗

TEMPORARILY_NOT_AVAILABLE

Status

OTHER

Sponsor class

Conditions

KRAS G12V Mutant Advanced Epithelial Cancers

Interventions

DRUG: Cyclophosphamide
DRUG: Gemcitabine
DRUG: Pembrolizumab
BIOLOGICAL: Cell Infusion

Sponsor

Providence Health & Services